What is Regemat 3D?
Founded in 2015, Regemat 3D operates at the intersection of regenerative medicine and advanced manufacturing. The company specializes in the design and production of sophisticated medical devices tailored for clinical applications, alongside the development of proprietary bioprinting systems. By providing the infrastructure necessary for tissue engineering and personalized medicine, Regemat 3D addresses critical gaps in clinical workflows. Their market position is defined by a commitment to bridging the divide between laboratory-scale bioprinting and scalable, real-world clinical implementation, making them a key contributor to the future of patient-specific therapeutic solutions.
How much funding has Regemat 3D raised?
Regemat 3D has raised a total of $553K across 1 funding round:
Other Financing Round
$553K
Other Financing Round (2022): $553K, investors not publicly disclosed
Key Investors in Regemat 3D
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Regemat 3D?
With the recent capital deployment, Regemat 3D is expected to focus on scaling its manufacturing capabilities and expanding its footprint in international clinical markets. The strategic roadmap likely involves enhancing the precision of their bioprinting hardware and deepening their integration into hospital-based clinical environments. As the firm moves into this next phase of growth, the focus will shift toward regulatory milestones and the commercialization of new bioprinting protocols. This trajectory suggests a move toward establishing a dominant standard in the regenerative medicine supply chain, leveraging their recent financing to outpace competitors in the rapidly evolving bio-fabrication space.
See full Regemat 3D company page
